AQSZF (Aequus Pharmaceuticals) Tariff Resilience Score: 5/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aequus Pharmaceuticals Tariff Resilience Score?

Aequus Pharmaceuticals AQSZF Tariff Resilience Score is 5 as of Jul. 22, 2026. The stock has 6 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Aequus Pharmaceuticals ranks better than 84.41% on this metric.

Aequus Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Aequus Pharmaceuticals has Aequus Pharmaceuticals Inc faces moderate tariff risks due to its international supply chain. Pharmaceuticals can be subject to tariffs, but industry exemptions and pricing strategies offer some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aequus Pharmaceuticals might have Average Resilient.

Aequus Pharmaceuticals  (OTCPK:AQSZF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aequus Pharmaceuticals Tariff Resilience Score Related Terms

AQSZF vs GCAN, STEK, CBSTQ: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aequus Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Aequus Pharmaceuticals (AQSZF) has a Tariff Resilience Score of 5 as of Jul. 22, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Aequus Pharmaceuticals ranks #160 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Aequus Pharmaceuticals' Tariff Resilience Score too high?
Aequus Pharmaceuticals' current Tariff Resilience Score is 5. Based on the distribution chart, Aequus Pharmaceuticals ranks #160 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Aequus Pharmaceuticals' Tariff Resilience Score compare to GCAN and STEK?
According to the Drug Manufacturers industry distribution chart, Aequus Pharmaceuticals ranks #160 out of 1026 companies for Tariff Resilience Score. This places Aequus Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Aequus Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aequus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aequus Pharmaceuticals (AQSZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 74% below its estimated fair value. The current Tariff Resilience Score is 5. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Aequus Pharmaceuticals (AQSZF), the current Tariff Resilience Score is 5 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aequus Pharmaceuticals Business Description

Address 200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan.